AER-01
COPD (Muco-obstructive Lung Disease)
Phase 2aActive
Key Facts
About Aer Therapeutics
Aer Therapeutics is a private, clinical-stage biotech targeting a significant unmet need in chronic obstructive pulmonary disease (COPD) and asthma: mucus plugs. Its lead asset, AER-01, is an inhaled small molecule therapy designed to cleave the chemical bonds that thicken mucus, aiming to clear airways, restore lung function, and reduce inflammation. The company has initiated a Phase 2a proof-of-concept study in COPD and is positioning itself as a pioneer in the mucolytic space for these prevalent respiratory conditions.
View full company profile